TITLE

Dual Induction of the Epo-Egr-TNF-α Plasmid in Hypoxic Human Colon Adenocarcinoma Produces Tumor Growth Delay

AUTHOR(S)
Salloum, Rabih M.; Mauceri, Helena J.; Weichselbaum, Ralph R.; Hanna, Nader N.; Gorski, David H.; Posner, Mitchell C.
PUB. DATE
January 2003
SOURCE
American Surgeon;Jan2003, Vol. 69 Issue 1, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Gene therapy is a modality for the treatment of solid tumors that involves the introduction of a suicide gene into the tumor cells. Genetic radiotherapy involves the placement of a radiation-sensitive promoter upstream from a suicide gene. Because of their irregular vasculature some solid tumors are chronically hypoxic and hence are resistant to conventional treatment with chemotherapy and ionizing radiation (IR). The purpose of this study was to demonstrate that regional tumor hypoxia could be exploited to improve local tumor control. The cDNA coding the erythropoietin hypoxia-responsive element (EPO) was placed upstream from the Egr-TNF-α construct. WIDR human colon adenocarcinoma cells were injected into the right hind limb of nude mice and treated with Epo-Egr-TNF-α plasmid with or without IR. Tumor volumes were measured by calipers and tumor necrosis factor (TNF)-α content of the tumor was determined by enzyme-linked immunosorbent assay. Treatment with the combined regimen of Epo-Egr-TNF-α plasmid + IR resulted in significant tumor growth delay. Tumor TNF-α content was increased by 30 per cent in the combined treatment group compared with each treatment alone. Regional tumor hypoxia can be exploited successfully to induce tumor growth delay, enhance local control, and enhance the therapeutic ratio.
ACCESSION #
10544872

 

Related Articles

  • Ionizing radiation: a genetic switch for cancer therapy. Mezhir, J. J.; Smith, K. D.; Posner, M. C.; Senzer, N.; Yamini, B.; Kufe, D. W.; Weichselbaum, R. R. // Cancer Gene Therapy;Jan2006, Vol. 13 Issue 1, p1 

    Gene therapy of cancer represents a promising but challenging area of therapeutic research. The discovery of radiation-inducible genes led to the concept and development of radiation-targeted gene therapy. In this approach, promoters of radiation-inducible genes are used to drive transcription...

  • Commentary: Systemic or regional chemotherapy: does it matter and should surgeons be involved? Stephens, F.O. // Journal of the Royal College of Surgeons of Edinburgh;Apr98, Vol. 43 Issue 2, p80 

    Comments on the use of tumor necrosis factor (TNF) as an immunological anti-cancer agent. Efficacy of the TNF in closed circuit perfusion techniques together with other anti-cancer agents; Treatment of multiple melanoma metastases; Difference of tumor response due to the use of regional...

  • Noninvasive Imaging of Therapeutic Gene Expression Using a Bidirectional Transcriptional Amplification Strategy. Ray, Sunetra; Paulmurugan, Ramasamy; Patel, Manish R.; Ahn, Byeong C.; Wu, Lily; Carey, Michael; Gambhir, Sanjiv S. // Molecular Therapy;Nov2008, Vol. 16 Issue 11, p1848 

    Promoters that limit transgene expression to tumors play a vital role in cancer gene therapy. Although tumor specific, the human Survivin promoter (pSurv) elicits low levels of transcription. A bidirectional two-step transcriptional amplification (TSTA) system was designed to enhance expression...

  • c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5. Kim, S Y; Kim, J-H; Song, J J // Cancer Gene Therapy;Feb2013, Vol. 20 Issue 2, p82 

    We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation of TRAIL receptors, which can sustain...

  • Systemic TNFα Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer. Su, Baowei; Cengizeroglu, Arzu; Farkasova, Katarina; Viola, Joana R.; Anton, Martina; Ellwart, Joachim W.; Haase, Rudolf; Wagner, Ernst; Ogris, Manfred // Molecular Therapy;Feb2013, Vol. 21 Issue 2, p300 

    Tumor necrosis factor alpha (TNFα) is a potent antitumoral cytokine, either killing tumor cells directly or affecting the tumor vasculature leading to enhanced accumulation of macromolecular drugs. Due to dose limiting side effects systemic administration of TNFα protein at therapeutically...

  • TRAIL Gene Therapy: From Preclinical Development to Clinical Application. Griffith, Thomas S.; Stokes, Brittany; Kucaba, Tamara A.; Earel Jr., James K.; VanOosten, Rebecca L.; Brincks, Erik L.; Norian, Lyse A. // Current Gene Therapy;Feb2009, Vol. 9 Issue 1, p9 

    Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 -- because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known...

  • Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Vardouli, L.; Lindqvist, C.; Vlahou, K.; Loskog, A. S. I.; Eliopoulos, A. G. // Cancer Gene Therapy;Nov2009, Vol. 16 Issue 11, p848 

    CD40, a tumor necrosis factor receptor family member, is an emerging target for cancer therapy being best appreciated as an important regulator of the anti-tumor immune response. In this study, we report the development of a replication-defective recombinant adenovirus (RAd) vector expressing...

  • Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFα-mediated apoptosis. Sanlioglu, Salih; Luleci, Guven; Thomas, Karl W // Cancer Gene Therapy;Nov2001, Vol. 8 Issue 11, p897 

    Lung cancer is the most frequently occurring cancer in the world and causes more deaths in the United States than does colon, breast, and prostate cancer combined. Despite advances in treatment modalities including radiation, surgery, and chemotherapy, the overall survival in lung cancer remains...

  • Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Kim, J-M; Ho, S-H; Hahn, W; Jeong, J-G; Park, E-J; Lee, H-J; Yu, S S; Lee, C-S; Lee, Y-W; Kim, S // Gene Therapy;Aug2003, Vol. 10 Issue 15, p1216 

    Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease. Among a number of techniques for gene transfer in vivo, the direct injection of plasmid DNA into muscle is simple,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics